<unk>  is used in combination with low dose aspirin to prevent thrombosis in patients with acute coronary syndrome, including unstable angina pectoris, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI), who are planned for treatment with PCI.<unk>  is associated with a higher bleeding risk compared to clopidogrel but has demonstrated superiority in reducing the composite endpoint of death, recurrent myocardial infarctions and stroke.<unk>  does not change the risk of death when given to people who have had a STEMI or NSTEMI. Given the risk of bleeding,<unk>  should not be used in people who are older than 75 years, who have low body weight or a history of transient ischemic attacks or strokes. The initiation of<unk>  before coronary angiography outside the context of primary PCI is not recommended.
Prasugrel
Ticagrelor
Elinogrel
Cetrorelix
Alteplase
Defibrotide
Oprelvekin
Eptifibatide